Thierry Hercend Ph.D

Thierry Hercend Ph.D General Information

Biography

Dr. Thierry Hercend serves as a Board Member at GreyWolf Therapeutics. He serves as the Chairman at GamaMabs Pharma. He serves as Board Member at Inotrem. He serves as Board Member at Complix. He also served as a Board Member at PegaOne. He serves as Venture Partner at Andera Partners. A medical doctor with a Ph.D. in immunology, Dr. Hercend has acquired more than 30 years of experience in the academic sector and the pharmaceutical industry in various therapeutic fields, including oncology and inflammatory diseases. Since 2006, he has been Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). From 2002 to 2005, Dr. Hercend was Vice President in charge of the therapeutic oncology sector for Aventis. From 1998 to 2002, he was Vice President (Europe) for research at Vertex Pharmaceuticals. He entered the pharmaceutical industry in 1990 at Roussel-Uclaf as Director of Therapeutic Immunology and then Scientific Director of the Health Division. Before joining the industrial sector, Dr. Hercend was responsible for the Immuno-Hematology laboratory at Gustave Roussy Villejuif Institute, France; director of the INSERM U333 unit dedicated to the immunology of tumors; and professor of immunology at Université de Médecine-Paris XI, France. He is the author of more than 120 publications in oncology, autoimmune diseases and transplantation.